Corcept Therapeutics (CORT) Reports Q4 EPS of $0.77
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
Revenue Growth %: +54.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.77, versus $0.04 reported last year. Revenue for the quarter came in at $53.3 million, versus $23.8 million reported last year.
GUIDANCE:
Corcept Therapeutics sees FY2018 revenue of $275-300 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Guggenheim Reiterates Buy Rating on Oracle (ORCL)
- Citi upgrades Old Dominion Freight Line to Buy with $223 target
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
